tiprankstipranks
Theralase’s Rutherrin® Enhances Chemotherapy Success
Company Announcements

Theralase’s Rutherrin® Enhances Chemotherapy Success

Theralase Technologies (TSE:TLT) has released an update.

Don't Miss Our Christmas Offers:

Theralase Technologies Inc. has announced that its lead drug formulation, Rutherrin®, has shown promise in preclinical research for boosting chemotherapy efficacy and overcoming multidrug resistance in cancer treatments. The drug works by potentially inhibiting the function of drug-efflux pumps in cancer cells, leading to higher retention and effectiveness of various chemotherapeutic agents. This breakthrough could enhance the therapeutic response in cancer patients and address the challenge of treatment resistance.

For further insights into TSE:TLT stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskTheralase Expands US Bladder Cancer Study Sites
TipRanks Canadian Auto-Generated NewsdeskTheralase Expands Clinical Trial for Bladder Cancer
TipRanks Canadian Auto-Generated NewsdeskTheralase Expands Cancer Study with Promising Results
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App